Notably, even throughout anti-TB treatment, the LAG-3 levels in TB patients remained elevated compared to those in the HI group, highlighting the potential of LAG-3 as a sensitive biomarker during treatment (Figure 4F). Here, LAG3 is linked to tuberculosis.